SCHEMBL6597276

SCHEMBL6597276

Cc1nc(N(C)C2CCN(Cc3ccccc3)CC2)nc(N)c1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.62
ACHE P22303 1/20 0.48
DRD2 P14416 6/20 0.46
DRD4 P21917 5/20 0.46
DRD3 P35462 5/20 0.46
GMNN O75496 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
HPGD P15428 2/20 0.46
PMP22 Q01453 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
TP53 P04637 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
SCN1A P35498 5/20 0.44
SCN8A Q9UQD0 5/20 0.44
SIGMAR1 Q99720 2/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6593408 0.91 SLC2A1 (0.52) SLC2A1ACHEDRD2DRD4DRD3
SCHEMBL6588987 0.89 SLC2A1 (0.53) SLC2A1ACHEDRD4ALDH1A1SCN1A
SCHEMBL6587608 0.87 SLC2A1 (0.48) SLC2A1ACHEDRD4ALDH1A1CYP3A4
SCHEMBL6593436 0.79 SLC2A1 (0.56) SLC2A1ACHEDRD2DRD4DRD3
SCHEMBL21375648 0.74 SIGMAR1 (0.60) ACHEDRD2DRD4DRD3GMNN
SCHEMBL19311894 0.72 ACHE (0.62) ACHEDRD2DRD4DRD3SIGMAR1
SCHEMBL8406887 0.72 DRD2 (0.51) SLC2A1ACHEDRD2DRD4DRD3
SCHEMBL2108897 0.72 ACHE (0.66) ACHEDRD2DRD4DRD3SIGMAR1
SCHEMBL8408498 0.71 DRD2 (0.67) SLC2A1ACHEDRD2DRD4DRD3
SCHEMBL16346811 0.71 DRD2 (0.53) SLC2A1ACHEDRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0912552-B1 2,4-DIAMINOPYRIMIDINE DERIVATES AS DOPAMINE D4 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2004-04-21 EP disclosed
US-6395742-B1 PSYCHOLOGICAL DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2002-05-28 US disclosed